EV Biologics Corp., a Wyoming-based biotechnology company, has engaged Foley to facilitate the propriety development of its exosome technology and technical innovation.
In its announcement, the company cited Foley’s standing at the top of intellectual property law in biotechnology and organics and its specialty in stem cell and extracellular vesicle technology.
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer.
Related News
30 September 2024
Press Releases
Foley Continues Northern California Growth with Two Litigation Partners
Foley & Lardner LLP announced today that Rajiv Dharnidharka and Jeanette Barzelay have joined the firm’s San Francisco office as partners in its Business Litigation & Dispute Resolution Practice and Innovative Technology Sector.
27 September 2024
Press Releases
Foley Launches PEAK Partner Training Program, Furthers Commitment to Continuous Learning
Foley & Lardner LLP is pleased to announce the launch of PEAK (Partner Excellence Actionable Knowledge), a regular and comprehensive curriculum of programs and resources to support our partners and meet their needs of continuous growth, learning, and development.
27 August 2024
Pro Bono
Foley Secures Landmark Victory for Pro Bono Client in Federal and State Cases
Foley & Lardner LLP is proud to announce a series of significant pro bono victories on behalf of the San Francisco Zen Center, culminating in a clean sweep across both federal and state courts.